Market Newsdesk

July 31, 2026 7:08 pm

Avista Makes Annual Price Adjustment Filings in Idaho

Requests would result in lower natural gas prices Nov. 1, 2026, and higher electric prices effective Oct. 1, 2026

SPOKANE, Wash., July 31, 2026 (GLOBE NEWSWIRE) — Avista (NYSE: AVA) has made annual filings with the Idaho Public Utilities Commission (IPUC or Commission) that have no impact on Avista’s earnings. These filings seek to true-up the level of costs in customer rates with the actual level incurred by the Company.

Natural Gas Adjustment Filings

The Company filed three annual natural gas requests that, if approved, would update natural gas rates starting November 1, 2026 as shown below:

Purchased Gas Cost Adjustment (PGA): a decrease of approximately $2.5 million or 3.0%
Fixed Cost Adjustment (FCA): an increase of approximately $2.4 million or 2.8%
Natural Gas Energy Efficiency Adjustment: a decrease of approximately $1.4 million or 1.6%

Electric Adjustment Filings

The Company filed three annual electric requests that, if approved, would update electric rates starting November 1, 2026 as shown below:

Power Cost Adjustment (PCA): an increase of approximately $14.6 million or 4.2%
Fixed Cost Adjustment (FCA): an increase of approximately $4.0 million or 1.2%
Bonneville Power Administration Residential Exchange (ResEx) Program: a decrease of approximately $0.3 million or 0.1%

Customer Bills Resulting from these Filings

If the natural gas PGA, Energy Efficiency and FCA filings are approved, residential natural gas customers in Idaho using an average of 66 therms per month would see their monthly bills decrease from $59.28 to $58.38, a decrease of $0.90 per month, or approximately 1.5%. The proposed natural gas rate change would be effective Nov. 1, 2026.

The net effect, on a revenue basis, for the requested natural gas rate change by rate schedule are as follows:

	General Service – Schedule 101	-1.5%
	Large General Service – Schedules 111 & 112	-3.1%
	Interruptible Service – Schedules 131 & 132	0.0%
	Transportation Service – Schedule 146	0.0%
	Overall	-1.8%

If the electric PCA, FCA and ResEx filings are approved, residential electric customers in Idaho using an average of 939 kilowatt hours per month would see their monthly bills increase from $119.52 to $127.28, an increase of $7.76 per month, or approximately 6.5%. The proposed electric rate change would be effective Oct. 1, 2026.

The net effect, on an annual revenue basis, for the requested electric rate changes by rate schedule are as follows:

	Residential Service – Schedule 1	6.4%
	General Service – Schedules 11 & 12	3.2%
	Large General Service – Schedules 21 & 22	2.9%
	Extra Large General Service – Schedule 25	6.6%
	Extra Large General Service – Schedule 25P	7.9%
	Pumping Service – Schedules 31 & 32	2.6%
	Street & Area Lights – Schedules 42-49	1.0%
	Overall	5.3%

Purchased Gas Cost Adjustment (PGA)

PGA requests are typically filed annually to balance the actual cost of wholesale natural gas purchased by Avista to serve customers with the amount presently included in customer rates. Avista does not make a profit on, or markup, the wholesale cost of natural gas. PGAs ensure customers pay what Avista pays, dollar for dollar, only at a more predictable and stable rate throughout the year. These rate adjustments are driven primarily by lower wholesale natural gas prices observed during this past winter, which were below the amounts included in rates.

Fixed Cost Adjustment (FCA)

The electric and natural gas FCA is a mechanism designed to break the link between a utility’s revenues and customers’ energy usage. Avista’s actual revenue, based on kilowatt hour or therm sales, will vary, up or down, from the level included in a general rate case and approved by the Commission. This could be caused by changes in weather, energy conservation or other factors. Under the FCA, Avista’s revenues are adjusted each month based on the number of customers. The annual difference between revenues based on sales and the number of customers is surcharged or rebated to customers beginning in the following year. The proposed FCA rate adjustments are primarily driven by variations in customer usage related to weather and savings from participating in efficiency programs. The FCA mechanisms do not apply to Avista’s Electric Extra Large General and Street Lighting Service Schedules, nor to its Natural Gas Interruptible and Transportation Service Schedules.

Natural Gas Energy Efficiency Adjustment

The Energy Efficiency Adjustment is related to the funding of Avista’s natural gas energy efficiency programs, which are designed to provide a financial incentive or rebate for cost-effective energy efficiency measures. This adjustment aligns the amount that is collected in customer rates with the actual costs to operate the programs. The rate changes proposed reflect the Company’s request to set all collection rates to $0.00 per therm of usage effective November 1, 2026, in alignment with the Company’s recent request to suspend operations of its natural gas programs at the end of 2026. This temporary pause in Avista’s natural gas energy efficiency programs is to ensure these programs continue to deliver the greatest value to customers; the Company anticipates bringing these programs back as soon as the strong cost-effectiveness standards expected from such programs are once again achievable.

Power Cost Adjustment (PCA)

The PCA is an annual rate adjustment made to reflect the difference between the actual cost of generating and purchasing electric power to serve customers and the cost currently included in customer rates. The biggest reason for this year’s proposed increase is due to the expiration of a rate credit associated with the 2025 PCA, that expires October 1, 2026. That expiration, coupled with higher power costs and increased electricity use experienced this PCA year are the reasons for the rate increase.

Bonneville Power Administration Residential Exchange Adjustment

The Residential Exchange Program provides a share of the benefits of the federal Columbia River power system to the residential and small farm customers of the investor-owned utilities in the Pacific Northwest, including Avista. Avista applies the benefits it receives, which typically fluctuate from year to year, to customers as a credit in their monthly electric rates. Due to fluctuations in usage, Avista rebated to customers a level of benefits that was slightly lower than the level of benefits received from BPA. Through this filing Avista is seeking to slightly increase the level of benefits provided to qualifying customers in order to return the under-rebated balance.

Rate Application Procedure

Avista’s applications are proposals, subject to public review and a Commission decision. Copies of the applications are available for public review at the offices of both the Commission and Avista, and on the Commission’s website (puc.idaho.gov). Customers may file with the Commission written comments related to Avista’s filings. Customers may also subscribe to the Commission’s RSS feed on the Commission’s website to receive periodic updates via e-mail about the case. Copies of rate filings are also available on Avista’s website at myavista.com/rates.

If you would like to submit comments on the proposed rate change, you can do so by going to the Commission website or mailing comments to:

Idaho Public Utilities Commission
P.O. Box 83720
Boise, ID 83720-0074

About Avista Corp.

Avista Corp. is an energy company involved in the production, transmission and distribution of energy as well as other energy-related businesses. Avista Utilities is our operating division that provides electric service to 429,000 customers and natural gas to 386,000 customers. Our service territory covers 34,000 square miles in eastern Washington, northern Idaho and parts of southern and eastern Oregon, with a population of 1.5 million. AERC is an Avista subsidiary that, through its subsidiary AEL&P, provides retail electric service to 18,000 customers in the city and borough of Juneau, Alaska. Our stock is traded under the ticker symbol “AVA.” For more information about Avista, please visit avistacorp.com.

This news release contains forward-looking statements regarding the company’s current expectations. Forward-looking statements are all statements other than historical facts. Such statements speak only as of the date of the news release and are subject to a variety of risks and uncertainties, many of which are beyond the company’s control, which could cause actual results to differ materially from the expectations. These risks and uncertainties include, in addition to those discussed herein, all of the factors discussed in the company’s and the Quarterly Report on Form 10-Q for the quarter ended Mar. 31, 2026, and its Annual Report on Form 10-K for the year ended Dec. 31, 2025.

Avista Corp. and the Avista Corp. logo are trademarks of Avista Corporation.

SOURCE: Avista Corporation

To unsubscribe from Avista’s news release distribution, send a reply message to [email protected].

Contact:

Media: Lena Funston (509) 495-8090 [email protected]
Investors: Stacey Walters (509) 495-2046 [email protected]
Avista 24/7 Media Access (509) 495-4174

July 31, 2026 6:48 pm

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.–(BUSINESS WIRE)–
CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company’s newly appointed Executive Advisor, certain stock awards as an inducement material to Mr. McNally’s employment with CareDx.

CareDx granted 15,822 shares of common stock restricted stock units (RSUs) to Mr. McNally. The RSU awards were made pursuant to the Company’s 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

50% of the RSUs will vest on January 2, 2027, and 50% will vest on July 2, 2027 subject to the employee’s continued service through each vesting date.

CareDx is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About CareDx

CareDx is a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, CareDx is dedicated to improving patient outcomes. For more information, please visit www.caredx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260731951215/en/

CareDx

Media Contacts

Natasha Moshirian Wagner

[email protected]

Investor Relations

Nina Deka

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Oncology Health Medical Devices Health Technology Genetics Pharmaceutical Biotechnology

MEDIA:

Logo

July 31, 2026 6:35 pm

SABA Announces Notification of Sources of Distributions

SABA Announces Notification of Sources of Distributions

NEW YORK–(BUSINESS WIRE)–
Saba Capital Income & Opportunities Fund II (NYSE: SABA) (the “Fund”), a registered closed-end management investment company listed on the New York Stock Exchange, is notifying shareholders, prospective shareholders, and third parties of the sources of distributions pursuant to Section 19(a) of the Investment Company Act of 1940 (the “Investment Company Act”).

IMPORTANT INFORMATION REGARDING MONTHLY DISTRIBUTION

Distribution Notice. Pursuant to Section 19(a) of the Investment Company Act, the Fund is providing its shareholders with an estimate of the source of the Fund’s monthly distribution as required by current securities laws.

The Fund’s estimated sources of the distribution to be paid on July 31, 2026 and for the fiscal year 2026 year-to-date are as follows:

Estimated Allocations for the distribution to be paid on July 31, 2026 (estimated as of July 24, 2026):

Distribution Per Share	Net Investment Income Per Share and Percentage of Such Distribution Amount	Net Realized Short-Term Capital Gains Per Share and Percentage of Such Distribution Amount	Net Realized Long-Term Capital Gains Per Share and Percentage of Such Distribution Amount	Return of Capital Per Share and Percentage of Such Distribution Amount
$0.05800	$0.05800 (100.00%)	$0.00000 (0.00%)	$0.00000 (0.00%)	$0.00000 (0.00%)

Cumulative Estimated Allocations fiscal year-to-date as of June 30, 2026, for the fiscal year ending October 31, 2026:

Distribution Per Share	Net Investment Income Per Share and Percentage of Such Distribution Amount	Net Realized Short-Term Capital Gains Per Share and Percentage of Such Distribution Amount	Net Realized Long-Term Capital Gains Per Share and Percentage of Such Distribution Amount	Return of Capital Per Share and Percentage of Such Distribution Amount
$0.56400	$0.56400 (100.00%)	$0.00000 (0.00%)	$0.00000 (0.00%)	$0.00000 (0.00%)

Shareholders, prospective shareholders, and third parties should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s Plan (as defined below). The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of the Fund’s distribution to shareholders may be a return of capital. A return of capital may occur, for example, when some or all of the money that a shareholder invested in a Fund is paid back to them. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with “yield” or “income.” The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send a Form 1099-DIV to shareholders for the calendar year that will describe how to report the Fund’s distributions for federal income tax purposes.

The determination of the actual source of distributions can only be made at year-end. The actual source amounts of all Fund distributions will be included in the Fund’s annual or semi-annual reports. In addition, the tax treatment may differ from the accounting treatment used to calculate the source of the Fund’s distributions as shown on shareholders’ statements. Shareholders should refer to their Form 1099-DIV for the character and amount of distributions for income tax reporting purposes. The final determination of the source and tax characteristics of all distributions will be made after December 31, 2026 and reported to you on Form 1099-DIV early in 2027. Since each shareholder’s tax situation is unique, it may be advisable to consult a tax advisor as to the appropriate treatment of Fund distributions.

Effective on January 1, 2024, Saba Capital Management, L.P. replaced Franklin Templeton Advisers, Inc. as the investment adviser to Saba Capital Income & Opportunities Fund II (formerly known as the Templeton Global Income Fund). Performance of the Fund prior to January 1, 2024 is not attributable to Saba Capital Management, L.P.

Average Annual Total Return (in relation to the change in net asset value (NAV) for the 5-year period ended on June 30, 2026)¹	Annualized Distribution Rate (for the current fiscal period as a percentage of NAV as of June 30, 2026)²	Cumulative Total Return (in relation to the change in NAV for the current fiscal period through June 30, 2026)³	Cumulative Fiscal Year-To-Date Distribution Rate (as a percentage of NAV as of June 30, 2026)⁴
4.93%	9.07%	2.71%	5.96%

Fund Performance and Distribution Rate Information:

¹Average Annual Total Return in relation to NAV represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ended through June 30, 2026. Annual NAV Total Return is the percentage change in the Fund’s NAV over a year, assuming reinvestment of distributions paid.

²The Annualized Distribution Rate is the dollar value of distributions for the current fiscal period November 1, 2025 through June 30, 2026 (which includes the special dividend paid during the current fiscal period in January 2026) annualized as a percentage of the Fund’s NAV as of June 30, 2026. The level of distribution amount shown is not guaranteed and special dividends may or may not be paid in the future. Further, no conclusions should be drawn about the Fund’s investment performance from the amount or rate of distribution shown.

³Cumulative Total Return is the percentage change in the Fund’s NAV from October 31, 2025 through June 30, 2026, assuming reinvestment of distributions paid.

⁴The Cumulative Fiscal Year-To-Date Distribution Rate is the dollar value of distributions for the current fiscal period November 1, 2025 through June 30, 2026 (which includes the special dividend paid during the current fiscal period in January 2026) as a percentage of the Fund’s NAV as of June 30, 2026. The level of distribution amount shown is not guaranteed and special dividends may or may not be paid in the future. Further, no conclusions should be drawn about the Fund’s investment performance from the amount or rate of distribution shown.

Managed Distribution Plan. The above distribution was declared in accordance with the Fund’s currently effective managed distribution plan (the “Plan”), whereby the Fund will make monthly distributions to shareholders at a fixed amount of $0.058 per share. Thus, the distribution amount shown excludes special dividends (which are not paid pursuant to the plan). The Fund will generally distribute amounts necessary to satisfy the Fund’s Plan and the requirements prescribed by excise tax rules and Subchapter M of the Internal Revenue Code. The Plan is intended to provide shareholders with a constant, but not guaranteed, fixed minimum rate of distribution each month and is intended to narrow the discount between the market price and the net asset value of the Fund’s common shares, but there is no assurance that the Plan will be successful in doing so.

Under the Plan, to the extent that sufficient investment income is not available on a monthly basis, the Fund will distribute long-term capital gains and/or return of capital in order to maintain its managed distribution rate. As a result, long-term capital gains and/or return of capital may be a material source of any distribution. No conclusions should be drawn about the Fund’s investment performance from the amount of the Fund’s distributions or from the terms of the Fund’s Plan. The Board of Trustees (the “Board”) may amend the terms of the Plan or terminate the Plan at any time without prior notice to Fund shareholders. No level of distribution can be guaranteed. The amendment or termination of the Plan could have an adverse effect on the market price of the Fund’s common shares. The Plan is subject to the periodic review by the Board, including a yearly review of the annual minimum fixed rate to determine if an adjustment should be made.

Past Performance is No Assurance of Future Results. Investment return and principal value of an investment in the Fund will fluctuate. Shares, when sold, may be worth more or less than their original cost. Investors should consider the investment objective, risks and expenses carefully. You can obtain the Fund’s most recent periodic reports and filings by visiting https://www.sec.gov/edgar/browse/?CIK=828803&owner=exclude.

Other Information and Certain Risk Factors: The Fund’s investment objective is to provide investors with high current income, with a secondary goal of capital appreciation. There can be no assurance that the Fund will meet its investment objective. The Fund seeks to achieve this objective by investing globally in debt and equity securities of public and private companies, which includes, among other things, investments in closed‐end funds, special purpose acquisition companies (“SPACs”), reinsurance, and public and private debt instruments. The Fund also may utilize derivatives including but not limited to total return swaps, credit default swaps, options and futures, in seeking to enhance returns and/or to reduce portfolio risk.

The value of the Fund’s investments in equity securities of public and private, listed and unlisted companies and equity derivatives generally varies with the performance of the issuer and movements in the equity markets more generally. As a result, the Fund may suffer losses if it invests in equity instruments of issuers whose performance diverges from the Fund’s investment manager’s expectations or if equity markets generally move in a single direction and the Fund has not hedged against such a general move. The Fund invests in closed-end funds and SPACs, which are subject to additional risks and considerations. The performance of reinsurance-related securities and the reinsurance industry itself are tied to the occurrence of various triggering events, including but not limited to weather, natural disasters (hurricanes, earthquakes, etc.), non-natural large catastrophes and other specified events causing physical and/or economic loss. To the extent the Fund invests in reinsurance-related securities for which a triggering event occurs, losses associated with such event could result in losses to the Fund’s investment, and a series of major triggering events affecting a large portion of the reinsurance- related securities held by the Fund could result in substantial losses to the Fund’s investment. The Fund may invest in high yield securities, which are speculative in nature and are subject to additional risk factors such as increased possibility of default, illiquidity of the security, and changes in value based on changes in interest rates. Changes in short-term market interest rates may directly affect the yield on the Fund’s common shares. If such rates fall, the Fund’s yield may also fall. If interest rate spreads on bonds and loans owned by the Fund decline in general, the yield on the bonds and loans will likely fall and the value of such bonds and loans may decrease. When short-term market interest rates rise, because of the lag between changes in such short-term rates and the resetting of the floating rates on bonds and loans in the Fund’s portfolio, the impact of rising rates will be delayed to the extent of such lag. Because of the limited secondary market for certain bonds and loans, the Fund’s ability to sell such securities in a timely fashion and/or at a favorable price may be limited. An increase in the demand for bonds and loans may adversely affect the rate of interest payable on new bonds and loans acquired by the Fund, and it may also increase the price of bonds and loans purchased by the Fund in the secondary market. A decrease in the demand for bonds and loans may adversely affect the price of bonds and loans in the Fund’s portfolio, which would cause the Fund’s net asset value to decrease. Investment in foreign borrowers involves special risks, including but not limited to potentially less rigorous accounting requirements, differing legal systems and potential political, social and economic adversity. The Fund may engage in currency exchange transactions to seek to hedge, as closely as practicable, all of the economic impact to the Fund arising from foreign currency fluctuations. Other risks include, but are not limited to, the use of derivatives, the potential lack of diversification in the Fund’s portfolio, and the fact that the Fund’s portfolio may be concentrated in a small group of industries or industry sectors from time to time. Investors should consult the Fund’s filings with the Securities and Exchange Commission as well as the materials on the Fund’s website for a more detailed discussion of these or other risk factors that affect the Fund.

About Saba Capital Income & Opportunities Fund II. Saba Capital Income & Opportunities Fund II is a publicly-traded registered closed-end management investment company. The Fund’s common shares trade on the New York Stock Exchange under the ticker symbol “SABA”. The Fund is managed by Saba Capital Management, L.P.

Forward-Looking Statements. This press release contains forward-looking statements subject to the inherent uncertainties in predicting future results and conditions. Any statements that are not statements of historical fact (including but not limited to statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. These statements are not guarantees of future performance, conditions or results and involve a number of risks and uncertainties. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements. These factors, including but not limited to the “Certain Risk Factors” noted above, are identified from time to time in the Fund’s filings with the Securities and Exchange Commission as well as the materials on the Fund’s website. The Fund undertakes no obligation to update such statements to reflect subsequent events, except as may be required by law.

For further information on Saba Capital Income & Opportunities Fund II, please visit our website at: www.sabacef.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260731080595/en/

Contact: 888-888-0319

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

July 31, 2026 6:33 pm

BRW Announces Notification of Sources of Distributions

BRW Announces Notification of Sources of Distributions

NEW YORK–(BUSINESS WIRE)–
Saba Capital Income & Opportunities Fund (NYSE: BRW) (the “Fund”), a registered closed-end management investment company listed on the New York Stock Exchange, is notifying shareholders, prospective shareholders, and third parties of the sources of distributions pursuant to Section 19(a) of the Investment Company Act of 1940 (the “Investment Company Act”).

IMPORTANT INFORMATION REGARDING MONTHLY DISTRIBUTION

The Fund’s estimated sources of the distribution to be paid on July 31, 2026 and for the fiscal year 2026 year-to-date are as follows:

Estimated Allocations for the distribution to be paid on July 31, 2026 (estimated as of July 24, 2026):

Distribution Per Share	Net Investment Income Per Share and Percentage of Such Distribution Amount	Net Realized Short-Term Capital Gains Per Share and Percentage of Such Distribution Amount	Net Realized Long-Term Capital Gains Per Share and Percentage of Such Distribution Amount	Return of Capital Per Share and Percentage of Such Distribution Amount
$0.08500	$0.08500 (100.00%)	$0.00000 (0.00%)	$0.00000 (0.00%)	$0.00000 (0.00%)

Cumulative Estimated Allocations fiscal year-to-date as of June 30, 2026, for the fiscal year ending October 31, 2026:

Distribution Per Share	Net Investment Income Per Share and Percentage of Such Distribution Amount	Net Realized Short-Term Capital Gains Per Share and Percentage of Such Distribution Amount	Net Realized Long-Term Capital Gains Per Share and Percentage of Such Distribution Amount	Return of Capital Per Share and Percentage of Such Distribution Amount
$0.68000	$0.68000 (100.00%)	$0.00000 (0.00%)	$0.00000 (0.00%)	$0.00000 (0.00%)

Effective after the close of business on June 4, 2021, Saba Capital Management, L.P. replaced Voya Financial as the investment adviser to Saba Capital Income & Opportunities Fund (formerly known as the Voya Prime Rate Trust). Performance of the Fund prior to the close of business on June 4, 2021 is not attributable to Saba Capital Management, L.P.

Average Annual Total Return (in relation to the change in net asset value (NAV) for the 5-year period ended on June 30, 2026)¹	Annualized Distribution Rate (for the current fiscal period as a percentage of NAV as of June 30, 2026)²	Cumulative Total Return (in relation to the change in NAV for the current fiscal period through June 30, 2026)³	Cumulative Fiscal Year-To-Date Distribution Rate (as a percentage of NAV as of June 30, 2026)⁴
7.53%	14.19%	-1.89%	9.25%

Fund Performance and Distribution Rate Information:

²The Annualized Distribution Rate is the dollar value of distributions for the current fiscal period November 1, 2025 through June 30, 2026 annualized as a percentage of the Fund’s NAV as of June 30, 2026. The level of distribution amount shown is not guaranteed and special dividends may or may not be paid in the future. Further, no conclusions should be drawn about the Fund’s investment performance from the amount or rate of distribution shown.

³Cumulative Total Return is the percentage change in the Fund’s NAV from October 31, 2025 through June 30, 2026, assuming reinvestment of distributions paid.

⁴The Cumulative Fiscal Year-To-Date Distribution Rate is the dollar value of distributions for the current fiscal period November 1, 2025 through June 30, 2026 as a percentage of the Fund’s NAV as of June 30, 2026. The level of distribution amount shown is not guaranteed and special dividends may or may not be paid in the future. Further, no conclusions should be drawn about the Fund’s investment performance from the amount or rate of distribution shown.

Managed Distribution Plan. The above distribution was declared in accordance with the Fund’s currently effective managed distribution plan (the “Plan”), whereby the Fund will make monthly distributions to shareholders at a fixed amount of $0.085 per share. Thus, the distribution amount shown excludes special dividends (which are not paid pursuant to the plan). The Fund will generally distribute amounts necessary to satisfy the Fund’s Plan and the requirements prescribed by excise tax rules and Subchapter M of the Internal Revenue Code. The Plan is intended to provide shareholders with a constant, but not guaranteed, fixed minimum rate of distribution each month and is intended to narrow the discount between the market price and the net asset value of the Fund’s common shares, but there is no assurance that the Plan will be successful in doing so.

Other Information and Certain Risk Factors: The Fund’s investment objective is to provide investors with a high level of current income, with a secondary goal of capital appreciation. There can be no assurance that the Fund will meet its investment objective. The Fund seeks to achieve this objective by investing globally in debt and equity securities of public and private companies, which includes, among other things, investments in closed‐end funds, special purpose acquisition companies (“SPACs”), reinsurance, and public and private debt instruments. The Fund also may utilize derivatives including but not limited to total return swaps, credit default swaps, options and futures, in seeking to enhance returns and/or to reduce portfolio risk.

The value of the Fund’s investments in equity securities of public and private, listed and unlisted companies and equity derivatives generally varies with the performance of the issuer and movements in the equity markets more generally. As a result, the Fund may suffer losses if it invests in equity instruments of issuers whose performance diverges from the Fund’s investment manager’s expectations or if equity markets generally move in a single direction and the Fund has not hedged against such a general move. The Fund invests in closed-end funds and SPACs, which are subject to additional risks and considerations. The performance of reinsurance-related securities and the reinsurance industry itself are tied to the occurrence of various triggering events, including but not limited to weather, natural disasters (hurricanes, earthquakes, etc.), non-natural large catastrophes and other specified events causing physical and/or economic loss. To the extent the Fund invests in reinsurance-related securities for which a triggering event occurs, losses associated with such event could result in losses to the Fund’s investment, and a series of major triggering events affecting a large portion of the reinsurance- related securities held by the Fund could result in substantial losses to the Fund’s investment. The Fund may invest in high yield securities, which are speculative in nature and are subject to additional risk factors such as increased possibility of default, illiquidity of the security, and changes in value based on changes in interest rates. Changes in short-term market interest rates may directly affect the yield on the Fund’s common shares. If such rates fall, the Fund’s yield may also fall. If interest rate spreads on bonds and loans owned by the Fund decline in general, the yield on the bonds and loans will likely fall and the value of such bonds and loans may decrease. When short-term market interest rates rise, because of the lag between changes in such short-term rates and the resetting of the floating rates on bonds and loans in the Fund’s portfolio, the impact of rising rates will be delayed to the extent of such lag. Because of the limited secondary market for certain bonds and loans, the Fund’s ability to sell such securities in a timely fashion and/or at a favorable price may be limited. An increase in the demand for bonds and loans may adversely affect the rate of interest payable on new bonds and loans acquired by the Fund, and it may also increase the price of bonds and loans purchased by the Fund in the secondary market. A decrease in the demand for bonds and loans may adversely affect the price of bonds and loans in the Fund’s portfolio, which would cause the Fund’s net asset value to decrease. The Fund’s use of leverage, if any, through borrowings or issuance of preferred shares can adversely affect the yield on the Fund’s common shares. Investment in foreign borrowers involves special risks, including but not limited to potentially less rigorous accounting requirements, differing legal systems and potential political, social and economic adversity. The Fund may engage in currency exchange transactions to seek to hedge, as closely as practicable, all of the economic impact to the Fund arising from foreign currency fluctuations. Other risks include, but are not limited to, the use of derivatives, the potential lack of diversification in the Fund’s portfolio, and the fact that the Fund’s portfolio may be concentrated in a small group of industries or industry sectors from time to time. Investors should consult the Fund’s filings with the Securities and Exchange Commission as well as the materials on the Fund’s website for a more detailed discussion of these or other risk factors that affect the Fund.

About Saba Capital Income & Opportunities Fund. Saba Capital Income & Opportunities Fund is a publicly-traded registered closed-end management investment company. The Fund’s common shares trade on the New York Stock Exchange under the ticker symbol “BRW”. The Fund is managed by Saba Capital Management, L.P.

For further information on Saba Capital Income & Opportunities Fund, please visit our website at: www.sabacef.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260731706623/en/

844-460-9411

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

July 31, 2026 6:27 pm

PicS N.V. 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against PicS N.V. – PICS

NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 4, 2026 to file lead plaintiff applications in a securities class action lawsuit against PicS N.V. (NasdaqGS: PICS) (“PicS” or the “Company”), if they purchased the Company’s Class A common stock in and/or traceable to its January 30, 2026 initial public offering (the “IPO”). This action is pending in the United States District Court for the Southern District of New York.

What You May Do

If you purchased shares of PicS as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 833-538-3615 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-pics/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by August 4, 2026.

About the Lawsuit

PicS and certain of its executives are charged with failing to disclose material information in the Offering Documents, violating federal securities laws.

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) in December 2025, the Company determined that its credit assessment procedures were deficient and required enhancement; (ii) following implementation of revised procedures, the Company reclassified approximately R$590 million of exposures from Stage 2 to Stage 3, resulting in an incremental ECL charge of R$88 million for the quarter ended December 31, 2025; (iii) the Company experienced an undisclosed Stage 3 formation rate exceeding 7% in the fourth quarter of 2025, materially departing from the historical trends disclosed in the offering documents; (iv) the offering documents materially overstated the effectiveness of PicS N.V.’s credit models, user data, and underwriting and risk-monitoring capabilities; and (v) prior to the IPO, PicS N.V.’s expansion into riskier business lines had led to deteriorating credit quality, increased default and impairment risk, and adverse financial and operational trends that were expected to continue worsening and materially impact the Company’s business and financial results.

The case is FirstFire Global Opportunities Fund, LLC v. PicS N.V., No. 26-cv-04793.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

View source version on businesswire.com: https://www.businesswire.com/news/home/20260731114422/en/

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
833-538-3615
1100 Poydras St., Suite 960
New Orleans, LA 70163

KEYWORDS: Louisiana New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo

July 31, 2026 6:25 pm

BE Investors Have Opportunity to Lead Bloom Energy Corporation Securities Fraud Lawsuit

PR Newswire

NEW YORK, July 31, 2026 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Bloom Energy Corporation (NYSE: BE) between February 27, 2025 and July 8, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 28, 2026.

So What: If you purchased Bloom Energy securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Bloom Energy class action, go to https://rosenlegal.com/cases/bloom-energy-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Bloom Energy obtained scandium through intermediaries who sourced the metal from China; (2) as a result, Bloom Energy understated the extent to which it relied on scandium from China; and (3) as a result of the foregoing, defendants’ positive statements about Bloom Energy’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Bloom Energy class action, go to https://rosenlegal.com/cases/bloom-energy-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/be-investors-have-opportunity-to-lead-bloom-energy-corporation-securities-fraud-lawsuit-302840374.html

SOURCE THE ROSEN LAW FIRM, P. A.

July 31, 2026 6:23 pm

GeneDx Holdings Corp. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against GeneDx Holdings Corp. – WGS

NEW YORK CITY & NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. (NasdaqGS: WGS) (“GeneDx” or the “Company”), if they purchased or otherwise acquired the Company’s shares between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Connecticut.

What You May Do

If you purchased shares of GeneDx as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 833-538-3615 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-wgs/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by August 3, 2026.

About the Lawsuit

GeneDx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company’s adjusted gross margins were deteriorating and were on track to fall from 74% to 69%; (ii) the Company was on track to miss its revenue estimates for both its exome and genome product lines; (iii) as a result, the Company would be forced to lower its full year revenue guidance to $475–$490 million, down from $540–$550 million; (iv) the Company’s prior acquisition of Fabric Genomics had not delivered the scalable, recurring revenue-generating platform the Company had touted, resulting in a $31.2 million impairment loss; and (v) as a result of the foregoing, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On this news, the price of GeneDx shares fell by $33.42 per share, or 49.2%.

The case is Basma v. GeneDx Holdings Corp., No. 26-cv-00880.

About Kahn Swick & Foti, LLC

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

View source version on businesswire.com: https://www.businesswire.com/news/home/20260731703257/en/

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

[email protected]

833-538-3615

1100 Poydras St., Suite 960

New Orleans, LA 70163

KEYWORDS: Louisiana New York United States North America

INDUSTRY KEYWORDS: Professional Services Class Action Lawsuit

MEDIA:

Logo

July 31, 2026 6:21 pm

BrilliA Incorporated Reports Fiscal Year 2026 Financial Results

BrilliA Incorporated Reports Fiscal Year 2026 Financial Results

Generated positive operating cash flow, returned $3.3 million to shareholders via dividends, maintained a debt-free balance sheet, and expects return to growth in fiscal 2027 on strengthening sales pipeline and brand portfolio expansion

SINGAPORE–(BUSINESS WIRE)–BrilliA Incorporated (NYSE American: BRIA) (“BrilliA” or the “Company”) today reported financial results for its fiscal year ended March 31, 2026.

Fiscal Year 2026 Highlights

Return to growth underway in fiscal 2027: Based on preliminary unaudited results for the first quarter ended June 30, 2026, revenue increased approximately 13% year-over-year, and the Company currently expects second-quarter revenue to increase approximately 30% year-over-year.
Generated positive operating cash flow of $0.3 million, an improvement of approximately $4.8 million compared to fiscal 2025, reflecting disciplined working capital management.
Remained profitable before income taxes, reporting pre-tax income of $0.3 million despite a challenging operating environment. After recognizing income tax expense of $0.3 million, results attributable to shareholders were near break-even at $(0.01) per diluted share.
Returned $3.3 million to shareholders through dividends, equivalent to approximately $0.13 per share.
Revenue was $49.0 million, compared to $64.4 million in fiscal 2025, reflecting order cancellations by U.S. brand customers and tariff-related disruptions.
Gross profit was $7.0 million, representing a gross margin of 14.3%, demonstrating resilient profitability despite lower production volumes.

“Fiscal 2026 demonstrated the resilience of our business model,” said Kendrew Hartanto, CEO of BrilliA. “Despite one of the most challenging operating environments our industry has faced in recent years, we generated positive operating cash flow, remained profitable before income taxes, maintained a debt-free balance sheet and returned $3.3 million to shareholders through dividends.”

“The U.S. tariff measures introduced during the year created significant disruption across global apparel supply chains and caused many of our U.S. brand customers to delay or cancel orders. Rather than pursuing uneconomic value, we remained disciplined, focused on high-quality customer relationships, managed working capital effectively, and protected our long-term profitability.”

“Just as importantly, we continued investing for the future. We retained our experienced workforce, expanded our sourcing capabilities, invested in product development and R&D, and accelerated the growth of our brand portfolio, including Diana and Jockey Indonesia, while advancing our collaboration with Ai Sakura in Japan and our manufacturing alliance with HH4K Group. With customer engagement improving and our sales pipeline strengthening, we believe fiscal 2027 marks the beginning of our return to growth.”

Operating Environment

Fiscal 2026 was characterized by significant disruption across the global apparel industry. The tariff measures announced by the U.S. administration in April 2025 prompted many international brands to reduce inventories, delay shipments against existing orders, and adopt a more cautious sourcing strategy. Although portions of the tariff framework were subsequently challenged in court, uncertainty surrounding trade policy and consumer demand continued throughout the year.

The operating environment became more challenging following the outbreak of the U.S.–Iran conflict in February 2026, which further weighted on customer purchasing activity during the final weeks of the fiscal year.

Against this backdrop, BrilliA remained focused on a disciplined commercial approach, prioritizing sustainable customer relationships, prudent risk management and cash generation while preserving the long-term strength of the business.

Fiscal Year 2026 Financial Review

Revenue for fiscal 2026 was $49.0 million compared to $64.4 million in the prior year, principally reflecting order cancellations and shipment delays by U.S. brand customers amid tariff-related uncertainty. The Company also extended targeted pricing support to certain customers to share a portion of tariff-related costs.

Gross profit was $7.0 million compared to $10.4 million in fiscal 2025. Gross margin remained resilient at 14.3% despite lower production volumes, supported by disciplined cost management and lower material costs, partially offset by lower manufacturing utilization and customer pricing support.

BrilliA remained profitable before income taxes, reporting pre-tax earnings of $0.3 million. Net cash provided by operating activities improved to $0.3 million from net cash used of $4.5 million in fiscal 2025, reflecting disciplined working capital management.

During the year, the Company paid $3.3 million in dividends to shareholders while maintaining a debt-free balance sheet. BrilliA ended fiscal 2026 with $5.1 million in cash and equivalents, no outstanding bank borrowings and shareholders’ equity of $14.7 million.

Investing Through the Cycle

Despite the temporary industry slowdown, BrilliA continued investing in capabilities that management believes will support long-term growth. The Company retained its experienced operational workforce, expanded sourcing capabilities, advanced product development and research initiatives, and continued investing in its manufacturing platform.

BrilliA also accelerated the expansion of its brand portfolio, including Diana and Jockey Indonesia, while pursuing growth opportunities in Malaysia and other Southeast Asian markets. Management believes these initiatives will diversify revenue streams, strengthen customer relationships and enhance long-term profitability.

Strategic and Operational Progress

During fiscal 2026 and subsequent to year-end, BrilliA advanced several initiatives designed to diversify revenue, expand its addressable market and improve utilization of its manufacturing platform.

Highlights included the commercial collaboration between Bra Pro Limited and Tokyo-based sportswear brand Ai Sakura, the manufacturing alliance with Hung Hon (4K) Limited, an exclusive 5-year Jockey® license in Indonesia, and sponsorship of the Mr. & Miss Pickleball Vietnam 2026 tournament to increase brand awareness for Diana.

Collectively, these initiatives strengthen BrilliA’s strategic positioning and support management’s objective of building a more diversified, higher-value business.

Outlook

BrilliA has entered fiscal 2027 with improving momentum. Based on preliminary unaudited results for the first quarter ended June 30, 2026, revenue increased approximately 13% compared with the prior-year period. Based on confirmed orders and the current sales pipeline, and barring significant adverse geopolitical or macroeconomic developments, the Company currently expects second-quarter revenue to increase approximately 30% year-on-year.

While the global operating environment remains subject to external uncertainties, management believes improving customer engagement, a strengthening sales pipeline, continued investment in its manufacturing platform and expanding business position, the Company will return to sustainable growth and create long-term shareholder value.

First-quarter figures are preliminary, unaudited, and based on management accounts. The Company’s second-quarter expectations constitute forward-looking statements subject to the risks described below.

Selected Financial Data

Consolidated Statements of Profit or Loss (USD in thousands, except per share data)

	FY2026	FY2025	FY2024
Revenue	48,988	64,391	55,964
Gross profit	6,984	10,431	8,640
Gross margin	14.3%	16.2%	15.4%
Profit before income taxes	263	3,619	3,989
Net (loss)/profit	(15)	2,819	3,284
(Loss)/earnings per share, basic and diluted	(0.01)	0.12	0.15

Selected Balance Sheet and Cash Flow Data (USD in thousands)

	March 31, 2026	March 31, 2025
Cash and cash equivalents	5,141	7,703
Total assets	27,212	28,408
Total shareholders’ equity	14,654	18,074
Net cash provided by/(used in) operating activities	261	(4,520)
Dividends paid	3,325	—

About BrilliA Incorporated

BrilliA Incorporated (NYSE American: BRIA) is a Singapore-based comprehensive one-stop service and solution provider for over 30 ladies’ intimate apparel brands worldwide, managing sourcing, design, prototyping, supply chain, logistics, and quality control. The Company works with major international companies, including Fruit of the Loom, HanesBrands Inc., and Jockey. Through its Diana brand, BrilliA also designs and markets apparel for active lifestyles. Find out more at brilliaincorporated.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of U.S. federal securities laws, including statements regarding BrilliA’s expected fiscal 2027 revenue growth, business strategy, market opportunities, future performance, and operational outlook. These forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including, but not limited to, global economic conditions, changes in trade policy and tariffs, geopolitical conflicts, supply chain disruptions, consumer demand, pricing pressures, customer order cancellations, and other factors described in the Company’s filings with the U.S. Securities and Exchange Commission (SEC).

BrilliA undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law. Investors are encouraged to review BrilliA’s filings with the SEC for additional risk factors.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260731095989/en/

Investor Contact

FNK IR

Matt Chesler, CFA

(+1) 646 809 2189

[email protected]

KEYWORDS: Singapore Southeast Asia Asia Pacific

INDUSTRY KEYWORDS: Retail Women Consumer Fashion

MEDIA:

Logo

July 31, 2026 6:02 pm

Ferguson Enterprises Set to Join S&P 500 and ADI Global Distribution to Join S&P SmallCap 600

PR Newswire

NEW YORK, July 31, 2026 /PRNewswire/ — S&P Dow Jones Indices will make the following changes to the S&P 500 and S&P SmallCap 600:

Ferguson Enterprises Inc. (NYSE: FERG) will replace Electronic Arts Inc. (NASD: EA) in the S&P 500 effective prior to the opening of trading on Wednesday, August 5. An investor consortium comprised of Public Investment Fund, Silver Lake, and Affinity Partners are acquiring Electronic Arts in a deal expected to be completed soon, pending final conditions.
ADI Global Distribution Inc. (NYSE: ADIG) will be added to the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, August 4, replacing Hertz Global Holdings Inc. (NASD: HTZ) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, August 5. S&P SmallCap 600 constituent Resideo Technologies Inc. (NYSE: REZI) is spinning off ADI Global Distribution in a transaction to be completed August 4. Hertz Global Holdings is no longer representative of the small-cap market space.

Following is a summary of the changes that will take place prior to the open of trading on the effective date:

Effective Date	Index Name	Action	Company Name	Ticker	GICS Sector
August 4, 2026	S&P SmallCap 600	Addition	ADI Global Distribution	ADIG	Information Technology

August 5, 2026	S&P SmallCap 600	Deletion	Hertz Global Holdings	HTZ	Industrials

August 5, 2026	S&P 500	Addition	Ferguson Enterprises	FERG	Industrials

August 5, 2026	S&P 500	Deletion	Electronic Arts	EA	Communication Services

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/.

FOR MORE INFORMATION:

S&P Dow Jones Indices

[email protected]

Media Inquiries

[email protected]

View original content:https://www.prnewswire.com/news-releases/ferguson-enterprises-set-to-join-sp-500-and-adi-global-distribution-to-join-sp-smallcap-600-302840407.html

SOURCE S&P Dow Jones Indices

July 31, 2026 5:59 pm

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

PR Newswire

– First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers

– On track for interim results reporting in 2H 2026

HOUSTON, July 31, 2026 /PRNewswire/ — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

Recent Highlights:

Clinical Updates:

Initiation of patient dosing in the Company’s Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs).
- Completed manufacturing of three batches of the CYWC628 drug product in accordance with FDA’s Good Manufacturing Practices (cGMP). Two of these batches have been released and the third batch will be released after it successfully passes all required safety and quality testing.

Financing:

Strengthened financial position through completion of a $9.0 million private placement with $3.0 million upfront and up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants. Additionally, closed a $3.0 million public offering.

Preclinical Progress:

Reported preclinical results suggesting that topical treatment with human dermal fibroblast (HDF) spheroids may reprogram the burn wound environment by dampening harmful inflammation, reshaping immune cell behavior, and reducing markers of scar-forming activity, within just eight days of injury.

Patent Portfolio:

Received a notice of an allowance for a patent with the U.S. Patent and Trademark Office (USPTO) covering methods of treating and accelerating the healing of wounds by topically administering a composition comprising 3D spheroid fibroblasts together or with one or more fibroblast-derived materials.
Filed a provisional patent application with the USPTO covering oral delivery systems designed to protect fibroblast-based therapeutics through the stomach and enable targeted release in the gastrointestinal tract.

Conference Presentations:

Presented poster presentations on the novel thymus organoid platform at the Keystone Symposia on Aging and Immunity; and preclinical data from its CYPS317 program for psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting.
Presented its proprietary thymus organoid technology to reboot the immune system and extend human life at the Alliance for Longevity Initiatives H-Span Summit in Washington DC.

Upcoming Milestones

Wound Healing:

Phase 1/2 clinical trial evaluating fibroblast-based spheroids product candidate, CYWC628, in DFU patients:
- Expects to report interim results in the second half of 2026.
- Anticipates completion and disclosure of primary safety and efficacy results by the end of 2026.

Psoriasis:

Anticipates IND clearance for the treatment of psoriasis with CYPS317, the Company’s fibroblast spheroid product candidate, in the fourth quarter of 2026.

Multiple Sclerosis:

Plans to submit an IND application with the U.S. Food & Drug Administration (FDA) for the treatment of multiple sclerosis with FibroBiologics’ fibroblast spheroid product candidate, CYMS101, in the fourth quarter of 2026.

Degenerative Disc Disease:

Plans to amend the IND clearance with the FDA to replace single-cell fibroblasts with fibroblast-derived chondrocyte spheroids derived from the CYWC628 master cell bank.

Pete O’Heeron, CEO and Founder of FibroBiologics, said, “With the first patient dosed in our CYWC628 trial, FibroBiologics has entered an important stretch as a clinical-stage company. Every milestone ahead builds on this one, and every data point will speak to what fibroblasts can do for patients. We are positioned for the catalysts ahead and eager to share our initial findings this year.”

Financial Highlights for the Quarter Ended June 30, 2026

Research and development expenses were approximately $1.7 million for the three months ended June 30, 2026, compared to approximately $2.0 million for the same period in 2025. The decrease was primarily due to decreased CRO costs of $0.3 million as clinical validation changed to manufacturing, and certain costs were capitalized to research and development supplies.

General and administrative expenses were approximately $2.4 million for both the three months ended June 30, 2026 and 2025. The primary areas of net change are decreased personnel expenses of $0.2 million; increased professional fees of $0.1 million for accounting, legal and marketing expenses; decreased facilities expenses of $0.1 million; and increased listing expenses of $0.1 million.

For the three months ended June 30, 2026, FibroBiologics reported a net loss of approximately $4.1 million. The net loss for the three months ended June 30, 2026, was primarily due to research and development expenses and general and administrative expenses discussed above.
Cash and cash equivalents totaled approximately $3.5 million at June 30, 2026.

For more information, please visit FibroBiologics’ website, email FibroBiologics at [email protected] or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the status, timing and plans for manufacturing FibroBiologics’ product candidates, the potential clinical benefits of fibroblasts and fibroblast-derived materials, plans for, and the anticipated timing of the initiation and completion of, FibroBiologics’ current and future preclinical studies, clinical trials, and research and development programs, the robustness, progress, and momentum of FibroBiologics’ research and development program, the potential indications for FibroBiologics’ programs, and plans for, and the timing of, regulatory filings. These forward-looking statements are based on FibroBiologics’ management’s current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics’ management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption “Risk Factors” and elsewhere in FibroBiologics’ annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC’s website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics’ liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; (d) the ability of FibroBiologics to successfully prosecute its patent applications; (e) FibroBiologics’ ability to manufacture its product candidates; (f) FibroBiologics’ ability to conduct clinical trials; and (g) the Company’s ability to maintain compliance with applicable Nasdaq rules. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:

[email protected]

Investor Relations:

Nic Johnson
Russo Partners
(212) 845-4242
[email protected]

Media Contact:

Liz Phillips
Russo Partners
(347) 956-7697
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-reports-second-quarter-2026-financial-results-progresses-clinical-trial-evaluating-lead-wound-care-candidate-302840401.html

SOURCE FibroBiologics, Inc.